Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Trinity Biotech (TRIB) over the last 6 years, with Q4 2020 value amounting to $4.4 million.

  • Trinity Biotech's Current Deferred Revenue rose 142226.03% to $4.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.4 million, marking a year-over-year increase of 142226.03%. This contributed to the annual value of $4.4 million for FY2020, which is 142226.03% up from last year.
  • According to the latest figures from Q4 2020, Trinity Biotech's Current Deferred Revenue is $4.4 million, which was up 142226.03% from $292000.0 recorded in Q4 2019.
  • Trinity Biotech's Current Deferred Revenue's 5-year high stood at $4.4 million during Q4 2020, with a 5-year trough of $224000.0 in Q4 2016.
  • For the 5-year period, Trinity Biotech's Current Deferred Revenue averaged around $1.1 million, with its median value being $292000.0 (2019).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 641.03% in 2019, then skyrocketed by 142226.03% in 2020.
  • Trinity Biotech's Current Deferred Revenue (Quarter) stood at $224000.0 in 2016, then grew by 24.11% to $278000.0 in 2017, then grew by 12.23% to $312000.0 in 2018, then fell by 6.41% to $292000.0 in 2019, then skyrocketed by 1422.26% to $4.4 million in 2020.
  • Its Current Deferred Revenue stands at $4.4 million for Q4 2020, versus $292000.0 for Q4 2019 and $312000.0 for Q4 2018.